Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: In vivo and in vitro analyses

American Journal of Transplantation

Volumn 6, Issue 9, 2006, Pages 2121-2133

  Fudaba, Y ^a   Spitzer, T R ^a   Shaffer, J ^a   Kawai, T ^a   Fehr, T ^a   Delmonico, F ^a   Preffer, F ^a   Tolkoff Rubin, N ^a   Dey, B R ^a   Saidman, S L ^a   Kraus, A ^a   Bonnefoix, T ^b,c,d   McAfee, S ^a   Power, K ^a   Kattleman, K ^a   Colvin, R B ^a   Sachs, D H ^a   Cosimi, A B ^a   Sykes, M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b INSTITUT ALBERT BONNIOT   (France)

^c UNIV GRENOBLE ALPES   (France)

^d HÔPITAL MICHALLON   (France)

Author keywords

Bone marrow transplantation; Kidney; Limiting dilution assay; Mixed chimerism; Multiple myeloma; Tolerance

Indexed keywords

BORTEZOMIB; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 2 RECEPTOR ALPHA; MELPHALAN; THALIDOMIDE; THYMOCYTE ANTIBODY; VINCRISTINE;

ADULT; ALLOIMMUNITY; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CD4+ CD25+ T LYMPHOCYTE; CHIMERA; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DRUG WITHDRAWAL; GRAFT VERSUS HOST REACTION; HELPER CELL; HLA MATCHING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE EPITHELIUM; LEUKOCYTE TRANSFUSION; LONG TERM CARE; MEMORY T LYMPHOCYTE; MULTIPLE MYELOMA; NONMYELOABLATIVE BONE MARROW TRANSPLANTATION; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL;

EID: 33746931587     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01434.x     Document Type: Article

References (45)

1. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989; 169: 493-502.
2. Sykes M, Szot GL, Swenson KA, Pearson DA. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997; 3: 783-787.
3. Huang CA, Fuchimoto Y, Scheier-Dolberg R, Murphy MC, Neville DM, Jr. Sachs DH. Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model. J Clin Invest 2000; 105: 173-181.
4. Kawai T, Cosimi AB, Colvin RB et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgous monkeys. Transplantation 1995; 59: 256-262.
5. Kimikawa M, Sachs DH, Colvin RB, Bartholemew A, Kawai T, Cosimi AB. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation 1997; 64: 709-716.
6. Sykes M, Sheard MA, Sachs DH. Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med 1988; 168: 2391-2396.
7. Pelot MR, Pearson DA, Swenson K et al. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based non-myeloablative conditioning regimen. Biol Blood Marrow Transplant 1999; 5: 133-143.
8. Mapara MY, Kim Y-M, Marx J, Sykes M. DLI-mediated GVL effects in mixed chimeras established with a non-myeloablative conditioning regimen: Extinction of GVL effects coincides with loss of alloreactive cells following conversion to full donor chimerism. Transplantation 2003; 76: 297-305.
9. Mapara MY, Kim Y-M, Wang S-P, Bronson R, Sachs DH, Sykes M. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: A critical role for host antigen-presenting cells. Blood 2002; 100: 1903-1909.
10. Spitzer TR, MCafee S, Sackstein R et al. The intentional induction of mixed chimerism and achievement of anti-tumor responses following non-myeloablative conditioning therapy and HLA-matched and mismatched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000; 6: 309-320.
11. Spitzer TR, MCafee S, Dey BR et al. Non-myeloablative haploidentical stem cell transplantation using anti-CD2monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation 2003; 75: 1748-1751.
12. Dey BR, MCafee S, Sackstein R et al. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant 2001; 7: 604-612.
13. Dey BR, MCafee S, Colby C et al. Impact of prophlactic donor leukocyte infusions on mixed chimerism, graft-vs-host disease and anti-tumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2003; 9: 320-329.
14. Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7-11.
15. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: Proof of principle. Blood 1996; 87: 1196-1198.
16. Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206-4211.
17. Bjorkstrand BB, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711-4718.
18. Spitzer TR, Delmonico F, Tolkoff-Rubin N et al. Combined HLA-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999; 68: 480-484.
19. Buhler LH, Spitzer TR, Sykes M et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74: 1405-1409.
20. Sykes M, Preffer F, McAfee S et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353: 1755-1759.
21. Inoue CN, Kondo Y, Ohnuma S, Morimoto T, Nishio T, Iinuma K. Use of cultured tubular cells isolated from human urine for investigation of renal transporter. Clin Nephrol 2000; 53: 90-98.
22. Racusen LC, Monteil C, Sgrignoli A et al. Cell lines with extended in vitro growth potential from human renal proximal tubule: Characterization, response to inducers, and comparison with established cell lines. J Lab Clin Med 1997; 129: 318-329.
23. Koenecke C, Shaffer J, Alexander S et al. NK cell recovery, chimerism, function and recognition in recipients of haploidentical hematopioetic cell transplantation following non-myeloablative conditioning using a humanized anti-CD2 mAb, Medi-507. Exp Hematol 2003; 31: 911-923.
24. Kraus AB, Shaffer J, Toh HC et al. Early host CD8 T-cell recovery and sensitized anti-donor IL-2-producing and cytolytic T-cell responses associated with marrow graft rejection following non-myeloablative bone marrow transplantation. Exp Hematol 2003; 31: 609-621.
25. Bonnefoix T, Bonnefoix P, Perron P et al. Quantitating effector and regulatory T lymphocytes in immune responses by limiting dilution analysis modeling. J Immunol 2005; 174: 3421-3431.
26. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens [see comments]. Blood 1999; 93: 2336-2341.
27. Buszello H, Ackermann R. Expression of HLA class-I antigens on renal cell carcinoma and non-transformed renal tissue. Eur Urol 1992; 21: 70-74.
28. Beck Y, Sekimata M, Nakayama S et al. Expression of human minor histocompatibility antigen on cultured kidney cells. Eur J Immunol 1993; 23: 467-472.
29. Kim YM, Mapara MY, Down JD et al. Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning. Blood 2004; 103: 732-739.
30. Dey BR, MCafee S, Colby C et al. Anti-tumor response despite loss of donor chimerism in patients treated with nonmyeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol 2005; 128: 351-359.
31. O'Donnell PV, Luznik L, Jones RJ et al. Nonmyeloablative bone marrow transplantation from partially HLA- mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8: 377-386.
32. Rubio MT, Kim YM, Sachs T, Mapara M, Zhao G, Sykes M. Anti-tumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: Critical role for recipient-derived IFN-{gamma}. Blood 2003; 102: 2300-2307.
33. Rubio MT, Saito TI, Kattelman K, Zhao G, Buchli J, Sykes M. Mechanisms of the anti-tumor responses and host-versus graft reactions induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: A critical role for recipient CD4+ T cells and recipient leukocyte infusion-derived IFN-gamma-producing CD8+ T cells. J Immunol 2005; 175: 665-676.
34. Lefkovits I, Waldmann H. Limiting Dilution Analysis of Cells of the Immune System. 2nd Ed. Oxford, Oxford University Press, 1999.
35. Bonnefoix T, Bonnefoix P, Mi JQ, Lawrence JJ, Sotto JJ, Leroux D. Detection of suppressor T lymphocytes and estimation of their frequency in limiting dilution assays by generalized linear regression modeling. J Immunol 2003; 170: 2884-2894.
36. Eichmann K, Falk I, Melchers I, Simon MM. Quantitative studies on T cell diversity. I. Determination of the precursor frequencies for two types of streptococcus A specific helper cells in non-immune, polyclonally activated splenic T cells. J Exp Med 1980; 152: 477-492.
37. Eichmann K, Goronzy J, Hamann U et al. Clonal analysis of helper and cytolytic T cells: Multiple, independently regulated precursor sets at frequencies suggesting a limited repertoire. In Isolation, Characterization, and Utilization of T Lymphocyte Clones. Academic Press, 1982: 233-244.
38. Parrado A, Casares S, Prieto J, Carmona M, Vaquero A, Rodriguez-Fernandez JM. Repopulation of circulating T, B and NK lymphocytes following bone marrow and blood stem cell transplantation. Hematol Cell Ther 1997; 39: 301-306.
39. Davison GM, Novitzky N, Kline A et al. Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Transplantation 2000; 69: 1341-1347.
40. Roberts MM, Lo LB, Gillis D et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12: 469-475.
41. Collins AB, Schneeberger EE, Pascual MA et al. Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208-2214.
42. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
43. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
44. Schmidtko J, Wang R, Wu CL et al. Posttransplant lymphoproliferative disorder associated with an Epstein- Barr-related virus in cynomolgus monkeys. Transplantation 2002; 73: 1431-1439.
45. Taswell C. Limiting diluton assays for the determination of immunocompetent cell frequencies. III. Validity tests for the single-hit Poisson model. J Immunol Methods 1984; 72: 29-40.